{"id":68289,"date":"2026-09-21T08:07:10","date_gmt":"2026-09-21T08:07:10","guid":{"rendered":"https:\/\/www.evaluate.com\/%e3%82%ab%e3%83%86%e3%82%b4%e3%83%aa%e3%83%bc%e3%81%aa%e3%81%97\/cns-dealmaking-has-become-more-selective\/"},"modified":"2026-11-06T14:45:08","modified_gmt":"2026-11-06T14:45:08","slug":"cns-dealmaking-has-become-more-selective","status":"publish","type":"post","link":"https:\/\/www.evaluate.com\/ja\/blog\/cns-dealmaking-has-become-more-selective\/","title":{"rendered":"CNS Dealmaking has Become More Selective"},"content":{"rendered":"

CNS drug development has had a significant revival. Anti-amyloid agents like Leqembi have shown meaningful slowing of Alzheimer’s progression, and Cobenfy’s 2024 approval marked the first non-dopaminergic schizophrenia treatment in over 30 years. A therapeutic area that saw multiple big pharma exits just a decade ago is attracting capital again. We cover the full picture in the new Evaluate Spotlight CNS episode which is available here<\/a>.<\/p>\n

The M&A data reflects that renewed confidence. Deal volume<\/a> has risen from around 35 transactions per year pre-pandemic to over 50 annually since, and median deal size has climbed to around $500m. The BMS acquisition of Karuna for Cobenfy and J&J’s $14.6bn purchase of Intra-Cellular Therapeutics, which brought Caplyta across schizophrenia, bipolar disorder, and depression, are the headline examples. Acquirers are active and willing to move on well-differentiated, clinically validated assets.<\/p>\n

Licensing is a rather different story. Volume spiked during the low-interest-rate years, then contracted sharply. Median deal size has held, though, which we believe reflects a focus on higher standards rather than smaller budgets. Human proof-of-concept data is now table stakes and a compelling mechanism with inconclusive early data no longer draws serious interest.<\/p>\n

One thing that we discuss in the webinar<\/a> is that M&A and licensing are focusing on different indications. Acquisitions cluster in commercially established categories like pain, depression, Parkinson’s and Alzheimer’s, while licensing leans toward neurodegeneration, where licensees will take on more scientific risk for a novel mechanism. The split reflects different risk appetites.<\/p>\n

We also discuss the modalities that are drawing the most forward-looking interest. RNAi, brain-shuttle technologies, and oligonucleotides are all areas where the science is well ahead of the commercial playbook. Psychedelics, which is particular area of Emma\u2019s expertise remain a wait-and-see area. Two psilocybin compounds could reach the FDA soon<\/a>, but the care burden has slowed uptake and the commercial case<\/a> remains unproven.<\/p>\n

The full Evaluate Spotlight CNS webinar and report<\/a> go deeper (though the webinar is just 20 minutes), covering deal-structure trends, indication-level data, and where the next wave of assets is coming from.<\/p>\n

If you’re looking for data and insight to support your CNS strategy, or need guidance on your best next steps, get in touch to chat to our team<\/a>. You can also find detailed reports on many indications within CNS in Datamonitor Healthcare.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

CNS drug development has had a significant revival. Anti-amyloid agents like Leqembi have shown meaningful slo […]<\/p>\n","protected":false},"author":36,"featured_media":64497,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[33],"tags":[17,10,150,60],"content-hub":[],"template-style":[],"class_list":["post-68289","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog","tag-dealmaking","tag-forecasts-market-landscape","tag-portfolio-strategy","tag-strategy-and-commericial"],"acf":{"use_alternative_header_image":"No (delete to use alternative)","alternative_header_image":null,"banner_image":"","author_image":66085,"author":"Wen-Yu Huang","author_title":"Director","author_image_copy":66106,"author_copy":"Emma Wille","author_title_copy":"Senior Analyst","form_field":""},"yoast_head":"\nCNS Dealmaking has Become More Selective | Evaluate<\/title>\n<meta name=\"description\" content=\"CNS M&A is rebounding with larger, more selective deals while licensing tightens around proven data. Explore CNS trends in Evaluate Spotlight.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.evaluate.com\/ja\/blog\/cns-dealmaking-has-become-more-selective\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CNS Dealmaking has Become More Selective\" \/>\n<meta property=\"og:description\" content=\"CNS M&A is rebounding with larger, more selective deals while licensing tightens around proven data. Explore CNS trends in Evaluate Spotlight.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.evaluate.com\/ja\/blog\/cns-dealmaking-has-become-more-selective\/\" \/>\n<meta property=\"og:site_name\" content=\"Evaluate\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-21T08:07:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-06T14:45:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.evaluate.com\/wp-content\/uploads\/2026\/08\/episode-02-1024x576.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"576\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Carolyn.Hall@norstella.com\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@evaluatepharma\" \/>\n<meta name=\"twitter:site\" content=\"@evaluatepharma\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Carolyn.Hall@norstella.com\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":[\"Article\",\"BlogPosting\"],\"@id\":\"https:\\\/\\\/www.evaluate.com\\\/ja\\\/blog\\\/cns-dealmaking-has-become-more-selective\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.evaluate.com\\\/ja\\\/blog\\\/cns-dealmaking-has-become-more-selective\\\/\"},\"author\":{\"name\":\"Carolyn.Hall@norstella.com\",\"@id\":\"https:\\\/\\\/www.evaluate.com\\\/ja\\\/#\\\/schema\\\/person\\\/2baaceafd11cef7e8e13e05ff4638002\"},\"headline\":\"CNS Dealmaking has Become More Selective\",\"datePublished\":\"2026-09-21T08:07:10+00:00\",\"dateModified\":\"2026-11-06T14:45:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.evaluate.com\\\/ja\\\/blog\\\/cns-dealmaking-has-become-more-selective\\\/\"},\"wordCount\":395,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.evaluate.com\\\/ja\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.evaluate.com\\\/ja\\\/blog\\\/cns-dealmaking-has-become-more-selective\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.evaluate.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/episode-02.webp\",\"keywords\":[\"Dealmaking\",\"Forecasts & Market Landscape\",\"Portfolio Strategy\",\"Strategy & Commercial\"],\"articleSection\":[\"Blog\"],\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.evaluate.com\\\/ja\\\/blog\\\/cns-dealmaking-has-become-more-selective\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.evaluate.com\\\/ja\\\/blog\\\/cns-dealmaking-has-become-more-selective\\\/\",\"url\":\"https:\\\/\\\/www.evaluate.com\\\/ja\\\/blog\\\/cns-dealmaking-has-become-more-selective\\\/\",\"name\":\"CNS Dealmaking has Become More Selective | Evaluate\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.evaluate.com\\\/ja\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.evaluate.com\\\/ja\\\/blog\\\/cns-dealmaking-has-become-more-selective\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.evaluate.com\\\/ja\\\/blog\\\/cns-dealmaking-has-become-more-selective\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.evaluate.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/episode-02.webp\",\"datePublished\":\"2026-09-21T08:07:10+00:00\",\"dateModified\":\"2026-11-06T14:45:08+00:00\",\"description\":\"CNS M&A is rebounding with larger, more selective deals while licensing tightens around proven data. Explore CNS trends in Evaluate Spotlight.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.evaluate.com\\\/ja\\\/blog\\\/cns-dealmaking-has-become-more-selective\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.evaluate.com\\\/ja\\\/blog\\\/cns-dealmaking-has-become-more-selective\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/www.evaluate.com\\\/ja\\\/blog\\\/cns-dealmaking-has-become-more-selective\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.evaluate.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/episode-02.webp\",\"contentUrl\":\"https:\\\/\\\/www.evaluate.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/episode-02.webp\",\"width\":1920,\"height\":1080,\"caption\":\"Evaluate Spotlight - central nervous system\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.evaluate.com\\\/ja\\\/blog\\\/cns-dealmaking-has-become-more-selective\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.evaluate.com\\\/ja\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CNS Dealmaking has Become More Selective\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.evaluate.com\\\/ja\\\/#website\",\"url\":\"https:\\\/\\\/www.evaluate.com\\\/ja\\\/\",\"name\":\"Evaluate\",\"description\":\"Pharma commercial intelligence, news & analysis\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.evaluate.com\\\/ja\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.evaluate.com\\\/ja\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.evaluate.com\\\/ja\\\/#organization\",\"name\":\"Evaluate\",\"url\":\"https:\\\/\\\/www.evaluate.com\\\/ja\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/www.evaluate.com\\\/ja\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.evaluate.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/cropped-evaluate_norstella_logo_rgb.webp\",\"contentUrl\":\"https:\\\/\\\/www.evaluate.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/cropped-evaluate_norstella_logo_rgb.webp\",\"width\":829,\"height\":350,\"caption\":\"Evaluate\"},\"image\":{\"@id\":\"https:\\\/\\\/www.evaluate.com\\\/ja\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/evaluatepharma\",\"https:\\\/\\\/uk.linkedin.com\\\/company\\\/evaluatepharma\\\/\"],\"description\":\"Evaluate provides trusted data, intelligence, and consulting services to help pharmaceutical and life sciences organisations make better decisions across research, development, and commercial strategy. Evaluate\u2019s solutions combine proprietary datasets, expert analysis, and forecasting to support portfolio strategy, competitive intelligence, and market understanding across the global pharma landscape. Evaluate is part of Norstella.\",\"email\":\"marketing@evaluate.com\",\"telephone\":\"+44 (0)20 7377 0800\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.evaluate.com\\\/ja\\\/#\\\/schema\\\/person\\\/2baaceafd11cef7e8e13e05ff4638002\",\"name\":\"Carolyn.Hall@norstella.com\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/532de941b0ef716fc90d02d0e1b2c026e80b7386c9f69f95082cc1bf7689de0d?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/532de941b0ef716fc90d02d0e1b2c026e80b7386c9f69f95082cc1bf7689de0d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/532de941b0ef716fc90d02d0e1b2c026e80b7386c9f69f95082cc1bf7689de0d?s=96&d=mm&r=g\",\"caption\":\"Carolyn.Hall@norstella.com\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CNS Dealmaking has Become More Selective | Evaluate","description":"CNS M&A is rebounding with larger, more selective deals while licensing tightens around proven data. Explore CNS trends in Evaluate Spotlight.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.evaluate.com\/ja\/blog\/cns-dealmaking-has-become-more-selective\/","og_locale":"ja_JP","og_type":"article","og_title":"CNS Dealmaking has Become More Selective","og_description":"CNS M&A is rebounding with larger, more selective deals while licensing tightens around proven data. Explore CNS trends in Evaluate Spotlight.","og_url":"https:\/\/www.evaluate.com\/ja\/blog\/cns-dealmaking-has-become-more-selective\/","og_site_name":"Evaluate","article_published_time":"2026-09-21T08:07:10+00:00","article_modified_time":"2026-11-06T14:45:08+00:00","og_image":[{"width":1024,"height":576,"url":"https:\/\/www.evaluate.com\/wp-content\/uploads\/2026\/08\/episode-02-1024x576.png","type":"image\/png"}],"author":"Carolyn.Hall@norstella.com","twitter_card":"summary_large_image","twitter_creator":"@evaluatepharma","twitter_site":"@evaluatepharma","twitter_misc":{"\u57f7\u7b46\u8005":"Carolyn.Hall@norstella.com","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"2\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["Article","BlogPosting"],"@id":"https:\/\/www.evaluate.com\/ja\/blog\/cns-dealmaking-has-become-more-selective\/#article","isPartOf":{"@id":"https:\/\/www.evaluate.com\/ja\/blog\/cns-dealmaking-has-become-more-selective\/"},"author":{"name":"Carolyn.Hall@norstella.com","@id":"https:\/\/www.evaluate.com\/ja\/#\/schema\/person\/2baaceafd11cef7e8e13e05ff4638002"},"headline":"CNS Dealmaking has Become More Selective","datePublished":"2026-09-21T08:07:10+00:00","dateModified":"2026-11-06T14:45:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.evaluate.com\/ja\/blog\/cns-dealmaking-has-become-more-selective\/"},"wordCount":395,"commentCount":0,"publisher":{"@id":"https:\/\/www.evaluate.com\/ja\/#organization"},"image":{"@id":"https:\/\/www.evaluate.com\/ja\/blog\/cns-dealmaking-has-become-more-selective\/#primaryimage"},"thumbnailUrl":"https:\/\/www.evaluate.com\/wp-content\/uploads\/2026\/08\/episode-02.webp","keywords":["Dealmaking","Forecasts & Market Landscape","Portfolio Strategy","Strategy & Commercial"],"articleSection":["Blog"],"inLanguage":"ja","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.evaluate.com\/ja\/blog\/cns-dealmaking-has-become-more-selective\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.evaluate.com\/ja\/blog\/cns-dealmaking-has-become-more-selective\/","url":"https:\/\/www.evaluate.com\/ja\/blog\/cns-dealmaking-has-become-more-selective\/","name":"CNS Dealmaking has Become More Selective | Evaluate","isPartOf":{"@id":"https:\/\/www.evaluate.com\/ja\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.evaluate.com\/ja\/blog\/cns-dealmaking-has-become-more-selective\/#primaryimage"},"image":{"@id":"https:\/\/www.evaluate.com\/ja\/blog\/cns-dealmaking-has-become-more-selective\/#primaryimage"},"thumbnailUrl":"https:\/\/www.evaluate.com\/wp-content\/uploads\/2026\/08\/episode-02.webp","datePublished":"2026-09-21T08:07:10+00:00","dateModified":"2026-11-06T14:45:08+00:00","description":"CNS M&A is rebounding with larger, more selective deals while licensing tightens around proven data. Explore CNS trends in Evaluate Spotlight.","breadcrumb":{"@id":"https:\/\/www.evaluate.com\/ja\/blog\/cns-dealmaking-has-become-more-selective\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.evaluate.com\/ja\/blog\/cns-dealmaking-has-become-more-selective\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/www.evaluate.com\/ja\/blog\/cns-dealmaking-has-become-more-selective\/#primaryimage","url":"https:\/\/www.evaluate.com\/wp-content\/uploads\/2026\/08\/episode-02.webp","contentUrl":"https:\/\/www.evaluate.com\/wp-content\/uploads\/2026\/08\/episode-02.webp","width":1920,"height":1080,"caption":"Evaluate Spotlight - central nervous system"},{"@type":"BreadcrumbList","@id":"https:\/\/www.evaluate.com\/ja\/blog\/cns-dealmaking-has-become-more-selective\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.evaluate.com\/ja\/"},{"@type":"ListItem","position":2,"name":"CNS Dealmaking has Become More Selective"}]},{"@type":"WebSite","@id":"https:\/\/www.evaluate.com\/ja\/#website","url":"https:\/\/www.evaluate.com\/ja\/","name":"Evaluate","description":"Pharma commercial intelligence, news & analysis","publisher":{"@id":"https:\/\/www.evaluate.com\/ja\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.evaluate.com\/ja\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/www.evaluate.com\/ja\/#organization","name":"Evaluate","url":"https:\/\/www.evaluate.com\/ja\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/www.evaluate.com\/ja\/#\/schema\/logo\/image\/","url":"https:\/\/www.evaluate.com\/wp-content\/uploads\/2026\/07\/cropped-evaluate_norstella_logo_rgb.webp","contentUrl":"https:\/\/www.evaluate.com\/wp-content\/uploads\/2026\/07\/cropped-evaluate_norstella_logo_rgb.webp","width":829,"height":350,"caption":"Evaluate"},"image":{"@id":"https:\/\/www.evaluate.com\/ja\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/evaluatepharma","https:\/\/uk.linkedin.com\/company\/evaluatepharma\/"],"description":"Evaluate provides trusted data, intelligence, and consulting services to help pharmaceutical and life sciences organisations make better decisions across research, development, and commercial strategy. Evaluate\u2019s solutions combine proprietary datasets, expert analysis, and forecasting to support portfolio strategy, competitive intelligence, and market understanding across the global pharma landscape. Evaluate is part of Norstella.","email":"marketing@evaluate.com","telephone":"+44 (0)20 7377 0800"},{"@type":"Person","@id":"https:\/\/www.evaluate.com\/ja\/#\/schema\/person\/2baaceafd11cef7e8e13e05ff4638002","name":"Carolyn.Hall@norstella.com","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/secure.gravatar.com\/avatar\/532de941b0ef716fc90d02d0e1b2c026e80b7386c9f69f95082cc1bf7689de0d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/532de941b0ef716fc90d02d0e1b2c026e80b7386c9f69f95082cc1bf7689de0d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/532de941b0ef716fc90d02d0e1b2c026e80b7386c9f69f95082cc1bf7689de0d?s=96&d=mm&r=g","caption":"Carolyn.Hall@norstella.com"}}]}},"jetpack_featured_media_url":"https:\/\/www.evaluate.com\/wp-content\/uploads\/2026\/08\/episode-02.webp","_links":{"self":[{"href":"https:\/\/www.evaluate.com\/ja\/wp-json\/wp\/v2\/posts\/68289","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.evaluate.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.evaluate.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.evaluate.com\/ja\/wp-json\/wp\/v2\/users\/36"}],"replies":[{"embeddable":true,"href":"https:\/\/www.evaluate.com\/ja\/wp-json\/wp\/v2\/comments?post=68289"}],"version-history":[{"count":2,"href":"https:\/\/www.evaluate.com\/ja\/wp-json\/wp\/v2\/posts\/68289\/revisions"}],"predecessor-version":[{"id":68291,"href":"https:\/\/www.evaluate.com\/ja\/wp-json\/wp\/v2\/posts\/68289\/revisions\/68291"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.evaluate.com\/ja\/wp-json\/wp\/v2\/media\/64497"}],"wp:attachment":[{"href":"https:\/\/www.evaluate.com\/ja\/wp-json\/wp\/v2\/media?parent=68289"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.evaluate.com\/ja\/wp-json\/wp\/v2\/categories?post=68289"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.evaluate.com\/ja\/wp-json\/wp\/v2\/tags?post=68289"},{"taxonomy":"content-hub","embeddable":true,"href":"https:\/\/www.evaluate.com\/ja\/wp-json\/wp\/v2\/content-hub?post=68289"},{"taxonomy":"template-style","embeddable":true,"href":"https:\/\/www.evaluate.com\/ja\/wp-json\/wp\/v2\/template-style?post=68289"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}